1575-36-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-1,2-diaminobenzene is used as a chemical intermediate for the synthesis of isomeric bromo analogues of Benzo-1H-triazole. These analogues have potential applications as inhibitors of protein kinases, which are important targets for the development of new drugs to treat various diseases, including cancer and inflammatory disorders.
In the pharmaceutical industry, 3-Bromo-1,2-diaminobenzene plays a crucial role in the development of novel therapeutic agents by providing a structural framework for the design and synthesis of new compounds with improved biological activities and selectivity. The compound's unique chemical properties, such as the presence of a bromine atom and amino groups, make it an attractive starting material for the synthesis of various bioactive molecules.
Furthermore, 3-Bromo-1,2-diaminobenzene can also be used in the development of new drug delivery systems, as its chemical structure allows for the attachment of various functional groups and moieties that can enhance the solubility, stability, and bioavailability of the resulting compounds. This can lead to the development of more effective and safer drugs with improved pharmacokinetic and pharmacodynamic properties.

InChI:InChI=1/C6H7BrN2/c7-4-2-1-3-5(8)6(4)9/h1-3H,8-9H2

Upstream product

• 19613-76-4 1-bromo-2,3-dinitro-benzene 
• 273-13-2 benzo[1,2,5]thiadiazole 
• 95-54-5 1,2-diamino-benzene 
• 7138-15-0 3-bromo-2-nitrophenylamine 
• 591-19-5 m-Bromoaniline 
• 22034-13-5 4-Bromo-benzo[1,2,5]thiadiazole 
• 59255-95-7 2-bromo-6-nitroaniline 

Downstream Products

• 83741-35-9 4-bromo-1H-benzo[d]imidazole 
• 20223-87-4 4-bromo-2-methyl-1H-benzo[d]imidazole 
• 180127-86-0 1,1'-Dibenzyl-4,4'-dibromo-1H,1'H-[2,2']bibenzoimidazolyl 
• 180127-84-8 4,4'-Dibromo-1,1'-bis-(4-tert-butyl-benzyl)-1H,1'H-[2,2']bibenzoimidazolyl 
• 180127-81-5 4,4'-Dibromo-1,1'-bis-(4-dodecyl-benzyl)-1H,1'H-[2,2']bibenzoimidazolyl 
• 928387-76-2 C₁₄H₁₇BrN₂O 
• 928387-74-0 C₁₄H₁₇BrN₂O 
• 40644-16-4 4‐bromo‐1,3‐dihydrobenzoimidazol‐2‐one 
• 1431753-73-9 C₁₅H₁₄BrN₃ 
• 1431753-75-1 C₂₃H₁₉N₃ 
• 1431753-76-2 C₂₀H₁₃N₃ 
• 1431753-78-4 C₂₅H₂₄N₄ 
• 1431753-79-5 C₂₂H₁₈N₄ 
• 1431753-81-9 C₂₂H₁₈N₄ 

Relevant academic research and scientific papers

Design and synthesis of a novel series of (1′S,2R,4′S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor

We describe an efficient and convergent synthesis of a series of (1′S,2R,4′S)-3H-4′-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2′-bicyclo[2.2.2]octanes] displaying potency for the α7 nicotinic acetylcholine receptor (nAChR) and good selectivity vs. the re

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Regioselective Radical Arene Amination for the Concise Synthesis ofortho-Phenylenediamines

The formation of arene C-N bonds directly from C-H bonds is of great importance and there has been rapid recent development of methods for achieving this through radical mechanisms, often involving reactiveN-centered radicals. A major challenge associated with these advances is that of regiocontrol, with mixtures of regioisomeric products obtained in most protocols, limiting broader utility. We have designed a system that utilizes attractive noncovalent interactions between an anionic substrate and an incoming radical cation in order to guide the latter to the areneorthoposition. The anionic substrate takes the form of a sulfamate-protected aniline and telescoped cleavage of the sulfamate group after amination leads directly toortho-phenylenediamines, key building blocks for a range of medicinally relevant diazoles. Our method can deliver both free amines and monoalkyl amines allowing access to unsymmetrical, selectively monoalkylated benzimidazoles and benzotriazoles. As well as providing concise access to valuableortho-phenylenediamines, this work demonstrates the potential for utilizing noncovalent interactions to control positional selectivity in radical reactions.

CXCR4 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

PHENAZINE-BASED COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME

The present invention refers to including and compound phenacy relates to organic light emitting device. (by machine translation)

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

There are disclosed a series of quinuclidines having the Formula (I). which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.

INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Copolymer comprising anthracene and benzoselenadiazole, preparing method and uses thereof

A copolymer comprising anthracene and benzoselenadiazole, preparing method and uses thereof are disclosed. The copolymer is represented by formula (I), wherein n is a natural number from 10 to 1000, a is 1 or 2, b is 0, 1 or 2, X, Y are O, S, Se, SO2, N—R4 or R5—Si—R6; R4, R5, R6 are selected from C1-C20 straight-chain, branched-chain or cyclo alkyl or alkoxy; R1, R2 are unsubstituted, monosubstituted or polysubstituted functional group Ar1, and said Ar1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted C1-C40 straight-chain or branched-chain or cyclo alkyl, substituted or unsubstituted aryl or heteroaryl; R3, R7 are unsubstituted, monosubstituted or polysubstituted functional group Ar2, and said Ar2 is selected from hydrogen, cyano, substituted or unsubstituted C1-C40 straight-chain or branched-chain or cyclo alkyl, substituted or unsubstituted C1-C40 alkoxy, substituted or unsubstituted C6-C40 aryl, substituted or unsubstituted C6-C40 aralkyl, substituted or unsubstituted C6-C40 aryl alkoxy.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

L-shaped benzimidazole fluorophores: Synthesis, characterization and optical response to bases, acids and anions

Nine L-shaped benzimidazole fluorophores have been synthesized, computationally evaluated and spectroscopically characterized. These "half-cruciform" fluorophores respond to bases, acids and anions through changes in fluorescence that vary from moderate t